Cargando…

A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts

Background: Although the durable efficacy of immune checkpoint inhibitors (ICIs) in BLCA has been confirmed in numerous studies, not all patients benefit from their application in the clinic. Platelets are increasingly being found to be closely associated with cancer progression and metastasis; howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Dingshan, Li, Xiaowen, Qi, Tiezheng, Dai, Yuanqing, Liu, Neng, Li, Huihuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192868/ https://www.ncbi.nlm.nih.gov/pubmed/37214475 http://dx.doi.org/10.3389/fphar.2023.1187700

Ejemplares similares

ACSM6 overexpression indicates a non-inflammatory tumor microenvironment and predicts treatment response in bladder cancer: results from multiple real-world cohorts
por: Li, Zhiwei, et al.
Publicado: (2023)

ACER2 forms a cold tumor microenvironment and predicts the molecular subtype in bladder cancer: Results from real-world cohorts
por: Liu, Jinhui, et al.
Publicado: (2023)

An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts
por: Deng, Hao, et al.
Publicado: (2023)

Characterization of lung adenocarcinoma based on immunophenotyping and constructing an immune scoring model to predict prognosis
por: Liu, Mengfeng, et al.
Publicado: (2022)

Molecular vasculogenic mimicry–Related signatures predict clinical outcomes and therapeutic responses in bladder cancer: Results from real-world cohorts
por: Zhang, Chunyu, et al.
Publicado: (2023)

A glycosylation risk score comprehensively assists the treatment of bladder neoplasm in the real-world cohort, including the tumor microenvironment, molecular and clinical prognosis
por: Liu, Jinhui, et al.
Publicado: (2023)

A novel signature to predict the neoadjuvant chemotherapy response of bladder carcinoma: Results from a territory multicenter real-world study
por: Li, Huihuang, et al.
Publicado: (2022)

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study
por: Wei, Yongbao, et al.
Publicado: (2023)

An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer
por: Xiao, Zicheng, et al.
Publicado: (2022)

Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma
por: Deng, Dingshan, et al.
Publicado: (2022)

Risk stratification of adult T‐cell leukemia/lymphoma using immunophenotyping
por: Kagdi, Huseini H., et al.
Publicado: (2016)

Identification of a DNA Damage Response and Repair-Related Gene-Pair Signature for Prognosis Stratification Analysis in Hepatocellular Carcinoma
por: Chen, Yi, et al.
Publicado: (2022)

Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis
por: Cheng, Chunliang, et al.
Publicado: (2021)

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
por: Wei, An-Hua, et al.
Publicado: (2023)

Comprehensively analysis of immunophenotyping signature in triple-negative breast cancer patients based on machine learning
por: Tang, Lijuan, et al.
Publicado: (2023)

Radiomic Immunophenotyping of GSEA-Assessed Immunophenotypes of Glioblastoma and Its Implications for Prognosis: A Feasibility Study
por: Hsu, Justin Bo-Kai, et al.
Publicado: (2020)

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (−) Breast Cancer
por: Du, Feng, et al.
Publicado: (2022)

VRK1 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis In Vitro and In Vivo
por: Wu, Jiacheng, et al.
Publicado: (2022)

Sulforaphane and bladder cancer: a potential novel antitumor compound
por: Zuo, Mingshun, et al.
Publicado: (2023)

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
por: Zhang, Qiongwen, et al.
Publicado: (2023)

A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer
por: Liu, Zhi, et al.
Publicado: (2021)

Pharmacoepidemiology Research-Real-World Evidence for Decision Making
por: Bérard, Anick
Publicado: (2021)

Editorial: Real-world experience with CFTR modulator therapy
por: Tümmler, Burkhard, et al.
Publicado: (2023)

Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
por: Hu, Jiao, et al.
Publicado: (2022)

Immunophenotyping of Acute Inflammatory Exacerbations of Lung Injury Driven by Mutant Surfactant Protein-C: A Role for Inflammatory Eosinophils
por: Nguyen, Jacklyn, et al.
Publicado: (2022)

Methylxanthine Treatment in Patients Hospitalized for Acute Exacerbation of Chronic Obstructive Pulmonary Disease in China: A Real-World Study Using Propensity Score Matching Analysis
por: Zhan, Zijie, et al.
Publicado: (2022)

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context
por: Patkar, Nikhil, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor–Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study
por: Wang, Li, et al.
Publicado: (2021)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
por: Li, Na, et al.
Publicado: (2023)

Editorial: Big Data, Pharmacogenomics and Real-World Research in Pharmacology
por: Wei, James Cheng-Chung, et al.
Publicado: (2020)

Drug utilization research in Peru: Is real-world data available?
por: Rodríguez-Tanta, L. Yesenia, et al.
Publicado: (2023)

Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
por: Yang, Rui, et al.
Publicado: (2022)

Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
por: Jang, Ha Young, et al.
Publicado: (2022)

Flow cytometry for evaluating platelet immunophenotyping and function in patients with thrombocytopenia
por: Shen, Chih-Lung, et al.
Publicado: (2022)

Abnormal platelet immunophenotypes and percentage of giant platelets in myelodysplastic syndrome: A pilot study
por: Wu, Yi-Feng, et al.
Publicado: (2022)

Immunophenotypes Based on the Tumor Immune Microenvironment Allow for Unsupervised Penile Cancer Patient Stratification
por: Chu, Chengbiao, et al.
Publicado: (2020)

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China
por: Tang, Wenjiao, et al.
Publicado: (2023)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
por: Wang, Fang, et al.
Publicado: (2023)

Real World Data in Health Technology Assessment of Complex Health Technologies
por: Hogervorst, Milou A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4bnn0r9k01jajmv8vu96q2hbuv